Despite the large number of promising neuroprotective agents identified in experimental
traumatic brain injury (TBI) studies, none has yet shown meaningful improvements in long …

In this article, we review past and current experience in clinical trials of traumatic brain
injuries (TBIs), we discuss limitations and challenges, and we summarize current directions …

The clinical understanding of traumatic brain injury (TBI) and its manifestations is beginning
to change. Both clinicians and research scientists are recognizing that TBI and related …

Traumatic brain injury (TBI) of any severity has the potential to devastate the lives of patients
over minutes or hours. An intracranial hematoma can transform an active life to a vegetative …

Over the past decade many neuroprotective agents have been developed with the hope of
being able to improve outcome in patients with traumatic brain injury. Unfortunately, none of …

Traumatic brain injury (TBI) is one of the leading cause of death and long-term disability in
virtually every country. Advances in neurointensive care have resulted in steadily …

Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in Operation Iraqi
Freedom largely due to the emergence of blast-injury from attacks with improvised explosive …

Despite substantial investments by government, philanthropic, and commercial sources over
the past several decades, traumatic brain injury (TBI) remains an unmet medical need and a …

New neuroprotective therapies for severe traumatic brain injury (TBI) have not translated
from pre-clinical to clinical success. Numerous explanations have been suggested in both …

Clinical trials in traumatic brain injury (TBI) pose complex methodological challenges,
largely related to the heterogeneity of the population. The International Mission on …